NVCT NASDAQ
Nuvectis Pharma, Inc.
1W: -10.4%
1M: -11.4%
3M: -10.9%
YTD: +116.7%
1Y: +197.4%
3Y: +100.7%
$18.44
-0.05 (-0.27%)
Pre-Market: $19.23 (+0.79, +4.31%)
Weekly Expected Move ±9.8%
$16
$18
$20
$22
$24
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' -21.73.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (35)
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Average Price Target of $36.25
Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up – What’s Next?
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25 According to Brokerages
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Small-cap stocks with strong momentum grades and triple-digit YTD gains
Bank of New York Mellon Corp Buys Shares of 36,770 Nuvectis Pharma, Inc. $NVCT
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Receives $36.25 Consensus Target Price from Analysts
BlackRock Inc. Acquires New Stake in Nuvectis Pharma, Inc. $NVCT
Nuvectis Pharma To Participate in Upcoming Investor Conferences
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
Nuvectis Pharma reports results
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Nuvectis Pharma (NASDAQ:NVCT) Trading 1.1% Higher – Here’s What Happened
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
Catalyst Watch: SpaceX initiations, Sun Valley Conference, PepsiCo earnings
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
Biggest stock movers Tuesday: ABVX, AVAV, and more
Nuvectis Pharma shares slide 19% on pricing of $100M stock offering
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
Catalyst Watch: Jobs report, Honeywell aerospace spinoff, and the Bending Spoons IPO
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% – Should You Buy?
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why